HARMONY BIOSCIENCES HOLDINGS, INC.
boothcheck covers HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed June 27, 2026.
• Harmony is a profitable single-product specialty pharma whose entire franchise rests on WAKIX (pitolisant) for narcolepsy, a drug that crossed $868.5 million in net revenue in 2025 and is guided above $1 billion in 2026 [Source: company FY2025 results, January 2026]. • The defining risk is concentration: one drug, one indication driving nearly all revenue, with generic entry held off only by patent settlements that let copies launch no earlier than January 2030 [Source: company press release,
Is HRMY overvalued? See what's priced in →
296 institutional managers reported holding HRMY in 13F filings for the quarter ended 2026-03-31. Together they hold about 93% of the company; the top 10 hold 48%. 34 opened new positions that quarter. Held by BlackRock, Vanguard Group, FMR (Fidelity), among others. On the short side, 4.6M shares were sold short as of the 2026-06-15 count, about 8% of shares outstanding (5.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
HRMY's share count grew 1.5% over the past five years even with $100.00M spent on repurchases. It pays no dividend. Cash returned over the past three years: $100.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at HRMY over the trailing three years. Absence is a fact about the company, not a signal. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
HRMY's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-02 | -7.9% | -2.4% |
| 2023-11-01 | +24.4% | +27.3% |
| 2024-02-23 | -1.5% | -9.8% |
| 2024-05-01 | +3.5% | +2.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
HRMY's latest 8-K filings: 2026-07-16 (items 2.02, 5.02, 7.01, 9.01); 2026-05-14 (items 5.07); 2026-05-07 (items 2.02, 7.01, 9.01); 2026-04-14 (items 5.02, 7.01, 9.01); 2026-04-02 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.